High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 131-141

  Brunvand, M W ^a   Bensinger, W I ^a,d   Soll, E ^a   Weaver, C H ^a,e   Rowley, S D ^a   Appelbaum, F R ^a   Lilleby, K ^a   Clift, R A ^a   Gooley, T A ^a   Press, O W ^a   Fefer, A ^a   Storb, R ^a   Sanders, J E ^a   Martin, P L ^a   Chauncey, T ^a   Maziarz, R T ^c   Zuckerman, N ^c   Montgomery, P ^b   Dorn, R ^b   Weiden, P L ^d   Demirer, T ^a   Holmberg, L A ^a   Schiffman, K ^a   McSweeney, P A ^a   Maloney, D G ^a   Buckner, C D ^a   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b St Luke's Mountain States Tumor Institute   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Response Oncology Inc ^*

^e Response Oncology Inc   (United States)

Author keywords

Autologous; Autologous stem cell transplantation; Lymphoma; Marrow transplantation; Non Hodgkin's lymphoma; Total body irradiation

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRANULOCYTE; HODGKIN DISEASE; HUMAN; LENGTH OF STAY; LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIFE TABLES; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 9544239355     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
2. Langenmayer I, Weaver C, Buckner CD et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241-246.
3. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
4. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063-1083.
5. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-1347.
6. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
7. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
8. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-3163.
9. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected from recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
10. Bast RC, Ritz J, Lipton JM et al. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 1983; 43: 1389-1394.
11. Hill RS, Mazza P, Amos D et al. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 69-74.
12. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
13. Pene R, Appelbaum FR, Fisher L et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 1993; 11: 219-222.
14. Vose JM, Anderson J, Bierman PJ et al. Initial trial of PIXY321 (GM-CSF/IL-3 fusion protein) following high-dose chemotherapy and autologous bone marrow transplantation (ABMT) for lymphoid malignancy. J Clin Oncol 1993; 12: 366 (Abstr.).
15. Nemunaitis J, Appelbaum FR, Singer JW et al. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 1993; 82: 3273-3278.
16. Fefer A, Benyunes M, Higuchi C et al. Interleukin-2 ± lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 1993; 89: 2-7.
17. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
18. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, MA, 1994, pp 513-526.
19. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, MA, 1994, pp 454-481.
20. Cox DR. Regression models and life-tables (with discussions), Series B. J Roy Stat Soc 1972; 34: 187-220.
21. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant 1989; 4: 445-448.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Fisher LD, Van Belle G. Biostatistics: a Methodology for the Health Sciences. John Wiley: New York, 1993.
24. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall: London, 1990, p 35.
25. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
26. Liberti G, Pearce R, Taghipour G et al. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT registry data. Ann Oncol 1994; 5 (Suppl. 2): 151-153.
27. Appelbaum FR, Fefer A, Cheever MA et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58: 509-513.
28. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596-602.
29. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
30. Lundberg JH, Hansen RM, Chitambar CR et al. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991; 9: 1848-1859.
31. Petersen FB, Appelbaum FR, Buckner CD. Is there a graft-versus-lymphoma effect? In: Zander AR, Barlogie B (eds). Autologous Bone Marrow Transplantation for Hodgkin's Disease, non-Hodgkin's Lymphoma and Multiple Myeloma. Springer-Verlag: Berlin, 1993, pp 93-96.
32. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
33. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
34. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
35. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 1993; 329: 1219-1224.
36. Fefer A, Benyunes MC, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993; 20: 41-45.
37. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
38. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.